Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02465515 · ClinicalTrials.gov registry record · Phase 4
Effect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Subjects With Type 2 Diabetes Mellitus
A Phase 4 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 4
- Development phase
- 9,463
- Enrollment target
NCT02465515 is a Phase 4 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 9,463 participants.
The verdict
NCT02465515, a Phase 4 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 9,463 participants
- Enrollment target
Study Summary
Albiglutide is an analogue of glucagon-like peptide-1 (GLP-1), used to treat type 2 diabetes This study will test whether albiglutide affects the occurrence of major cardiovascular events such as heart attacks or strokes and other important medical outcomes in persons with type 2 diabetes, when used alone or added to other diabetes treatments.
Interventions
- BIOLOGICAL Albiglutide 30 mg
- BIOLOGICAL Albiglutide 50 mg
- BIOLOGICAL Albiglutide matching placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9,463 participants |
| Start Date | 2015-07-01 |
| Est. Completion | 2018-03-14 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02465515
The ClinicalTrials.gov registry entry for NCT02465515 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 9,463 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Albiglutide 30 mg is the first listed.
NCT02465515 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02465515 about?
NCT02465515 is a clinical study titled "Effect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Subjects With Type 2 Diabetes Mellitus". Albiglutide is an analogue of glucagon-like peptide-1 (GLP-1), used to treat type 2 diabetes This study will test whether albiglutide affects the occurrence of major cardiovascular events such as heart attacks or strokes and other important medical outcomes in persons with type 2 diabetes, when used...
What is the current status of trial NCT02465515?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 9,463 participants. The study started on 2015-07-01. Estimated completion is 2018-03-14.
What interventions are being tested in trial NCT02465515?
The interventions under investigation include: Albiglutide 30 mg (BIOLOGICAL), Albiglutide 50 mg (BIOLOGICAL), Albiglutide matching placebo (BIOLOGICAL).
Who is sponsoring clinical trial NCT02465515?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.